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Summary
Background.— A substantial number of patients with acute myocardial infarction (AMI) have
polyvascular disease (PolyVD), deﬁned as cerebrovascular disease (CVD), peripheral arterial
disease (PAD) or both.
Aim.— To investigate the impact of PolyVD on baseline characteristics, management and out-
comes.
Methods.— The Alliance project is a multicentre, cross-sectional database of patients with
myocardial infarction throughout France from 2000 to 2005. A pooled analysis of individual
patient data was performed by aggregating data from ﬁve registries, representing 9783 patients
hospitalized for acute coronary syndromes. Data were collected on history of PAD and CVD and
correlated to baseline characteristics, management and hospital outcomes.
Results.— Eight thousand nine hundred and four patients had full datasets for this analysis
(13% with a history of CVD or PAD, 87% without). Patients with PolyVD were older (72 vs 65
years, p < 0.0001), had a more frequent history of AMI (26% vs 15%, p < 0.0001), percutaneous
coronary intervention (PCI), coronary artery bypass graft (CABG), renal insufﬁciency (12% vs
3%, p < 0.0001) and consistently more risk factors for atherosclerosis (hypertension, dyslipi-
daemia, smoking, diabetes), but less frequently a body mass index > 30 kg/m2 (14.0% vs 20.1%,
p < 0.0001) compared to patients with coronary artery disease (CAD) alone. Killip class, left-
ventricular ejection fraction and GUSTO risk score were all worse among patients with PolyVD.
Management of patients with PolyVD was less aggressive (with later admission and less fre-
quent use of in-hospital angiography or evidence-based therapies at discharge). Mortality of
patients with PolyVD was consistently higher than in those with CAD alone, regardless of age.
Multivariable analysis, adjusting for age, showed that both PAD (odds ratio 1.36 95% conﬁdence
interval 1.03—1.79) and history of CVD (odds ratio 1.74, 95% conﬁdence interval 1.27—2.40)
were independent predictors of hospital mortality relative to patients with CAD only.
Conclusion.— Patients with PolyVD represented a substantial group among AMI patients, at
particularly high risk of death, yet were managed less aggressively than patients with CAD alone.
This was associated with markedly higher in-hospital mortality. Further research is warranted
to design and test strategies to decrease mortality in this high-risk subset.
© 2010 Published by Elsevier Masson SAS.
Résumé
Introduction.— Une proportion signiﬁcative de patients hospitalisés pour infarctus du myocarde
(IDM) présente une atteinte vasculaire extracoronarienne associée, déﬁnie par un accident
vasculaire cérébral (AVC), une atteinte artérielle périphérique (AAP) ou les deux. L’impact
de cette atteinte polyvasculaire sur les caractéristiques de ces patients, leur prise en charge
hospitalière et leur pronostic est mal connu.
Méthodes.— Le registre Alliance est une base de données multicentrique de patients admis pour
un IDM en France de 2000 à 2005. Le recueil des données a été réalisé en utilisant cinq registres
représentant 9783 patients hospitalisés pour syndrome coronarien aigu entre 2000 et 2005. Les
antécédents d’AVC ou d’AAP ont été colligés et corrélés aux caractéristiques cliniques, à la
prise en charge médicale et interventionnelle et à la mortalité hospitalière.
Résultats.— L’ensemble des données a pu être recueilli chez 8904 patients. Parmi eux, 13 %
avait une atteinte polyvasculaire, alors que 87% n’avaient pas d’antécédent d’AVC et d’AAP.
Les patients avec une atteinte vasculaire extracoronarienne étaient plus âgés (72 versus 65 ans,
p < 0,0001), avaient plus souvent des antécédents coronariens : antecedent d’IDM (26,1 versus
14,7 %, p < 0,0001), d’angioplastie, ou de pontage aortocoronarien, et d’insufﬁsance rénale
(11,9 % versus 2,5 %, p < 0,0001). La prévalence des facteurs de risque cardiovasculaire (hyper-
tension, dyslipidemie, tabac, diabète) était globalement plus importante, sauf pour l’obésité
(BMI > 30) (14,0 versus 20,1 %, p < 0,0001). De même, la classe Killip était plus élevée, la fraction
d’éjection plus basse et le score Gusto plus sévère. Leur prise en charge était moins agressive
avec un délai entre le début des symptômes et l’admission plus long, moins de coronarographie
et d’angioplastie (48 % versus 62 %, p < 0,0001), et une moindre prescription des quatre traite-
ments recommandés par les guidelines (antiagrégants plaquettaires, bêtabloquants, statines5% CI : 1,27—2,40) était un marqueur prédictif indépendant de
1,23—1,88], p < 0,0001).
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Conclusion.— L’atteinte vasculaire extracoronaire est fréquente chez les patients hospitalisés
pour IDM et identiﬁe un sous-groupe à haut risque avec des caractéristiques plus sévères, une
mortalité accrue mais une prise en charge moins agressive et un traitement médical moins
souvent optimal. Des études complémentaires sont nécessaires pour évaluer l’impact d’une
stratégie plus intensive sur la mo
© 2010 Publie´ par Elsevier Masso
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Cardiovascular disease, due to cerebrovascular disease
(CVD), peripheral arterial disease (PAD) or coronary artery
disease (CAD), is the leading cause of mortality and mor-
bidity in industrialized countries [1]. Atherothrombosis is a
common (but not exclusive) underlying cause of these three
diseases. Therefore, CVD, PAD and CAD are often different
locations of a similar underlying disease, share similar risk
factors (albeit with a different relative weight for each of
the locations) and frequently coexist [2]. In the REduction
of Atherothrombosis for Continued Health (REACH) Registry,
there was major overlap between the various locations of
the symptomatic location of the disease [3], and mortality
and morbidity increased with the extent of atherosclerotic
burden (i.e., number of arterial beds affected) [4].
Major advances have been made in the prevention, diag-
nosis and treatment of CAD. Randomized trials provide
robust evidence that pharmacological and interventional
therapies improve the outcome of patients with acute coro-
nary syndromes (ACS) and have led to changes in clinical
practice and guidelines [5—8]. Observational data from the
Global Registry of Acute Coronary Events (GRACE) [9] have
shown that in routine practice, improvement in the man-
agement of patients with ACS is associated with a signiﬁcant
rate reduction in heart failure, acute myocardial infarction
(AMI) and death. In contrast, patients with non-coronary
atherosclerotic vascular disease, and especially PAD, are
regarded as particularly high-risk, yet are often underdiag-
nosed and undertreated [10—12]. For example, patients with
PAD, compared to those with CAD, were less likely to be
treated with aspirin or lipid-lowering therapy if they were
hypercholesterolaemic [13].
Acute myocardial infarction is the most frequent and
potentially fatal event in patients with cardiovascular dis-
ease, and the impact of the association of PAD or CVD on the
management and outcome of patients hospitalized for AMI
has not been fully evaluated. We hypothesized that a history
of PAD or CVD may affect clinical presentation, management
and outcome. We therefore used data from the Alliance
consortium of AMI to compare baseline characteristics, man-
agement and in-hospital outcomes of patients with AMI alone
with those of patients with associated CVD or/and PAD.
Methods
Study designThe Alliance project is a multicentre, cross-sectional
database of 9783 patients admitted for AMI throughout
France from 2000 to 2005. The purpose of the project is to
provide aggregate data and test hypotheses regarding AMI
in France. It is a pooled analysis of data from ﬁve registries:
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ACT (2003 nationwide survey with 2517 patients) [14], USIC
2000 nationwide survey with 2315 patients) [15,16], RICO
2000—2005 continuous registry department of Burgondy
ith 4057 patients) [17], Paris (2000—2005 continuous reg-
stry of University Hospital Pitié-Salpétrière Paris with 652
atients) [18] and eParis (2000—2005 continuous registry
ith 242 patients). All patients gave informed consent for
articipation in the survey and follow-up.
eﬁnitions
cute myocardial infarction was deﬁned as an increase in
ne cardiac biochemical marker of necrosis (troponin I or
or creatine phosphokinase [CPK] MB) at least twice the
pper normal limit [19] and at least one of the follow-
ng criteria: chest pain lasting for at least 20minutes not
elieved by nitrates, electrocardiographic changes on at
east two contiguous leads with persisting ST elevation or
epression ≥ 0.1mV and/or pathological Q waves. Patients
ere classiﬁed into three categories: ST-segment elevation
yocardial infarction (STEMI), non-ST-segment elevation
yocardial infarction (NSTEMI) [20] or undetermined elec-
rocardiographic pattern (left bundle-branch block or paced
hythm).
ascular disease
iagnosis of PAD was made on the basis of the presence
f one of the following: history of claudication, peripheral
ascular surgery, vascular angioplasty or amputation or doc-
mented abdominal aortic aneurysm. The diagnosis of CVD
as based on a history of transient ischaemic attack (TIA),
toke, carotid endarterectomy or carotid stent implanta-
ion. TIA was deﬁned as a history of loss of neurological
unction caused by ischaemia that was abrupt in onset but
ith complete return of function within 24 hours. Stroke
as deﬁned as a loss of neurological function caused by an
schaemic event, with residual symptoms.
ata collection
ata regarding patient demographics, risk factors, medical
istory, clinical presentation, prehospital delay, in-hospital
anagement and in-hospital mortality were collected. Poly-
ascular disease (PolyVD) was deﬁned as patients with CVD,
AD or both. Items used for the pooled analysis were deﬁned
n a similar manner across registries, using simple clinical
eﬁnitions.tatistical analysis
ata are presented as number of patients (per cent)
r mean± standard deviation (SD). Differences in base-
ine characteristics, hospital management and mortality
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Table 1 Clinical characteristics of the overall population and according to the presence or absence of polyvascular
disease (PolyVD).
Variable Overall (n = 8904) No PolyVD (n = 7743) PolyVD (n = 1161) p
Age (years) 66± 14 65± 14 72± 12 < 0.0001
Men 6409 (72) 5550 (72) 859 (74) 0.10
Cardiovascular risk factors
Hypertension 4455 (50) 3691 (48) 764 (66) < 0.0001
Diabetes 1830 (21) 1435 (19) 395 (34) < 0.0001
Dyslipidaemia 3867 (43) 3317 (43) 550 (47) 0.004
History of smoking (current or former) 5277 (59) 4543 (59) 734 (63) 0.003
Obesity (body mass index ≥30 kg/m2) 1606 (19) 1457 (20) 149 (14) < 0.0001
Renal insufﬁciency (glomerular ﬁltration
rate ≤30mL/min)
239 (4) 140 (3) 99 (12) < 0.0001
History of coronary artery disease
Myocardial infarction 1441 (16) 1138 (15) 303 (26) < 0.0001
Percutaneous coronary intervention 943 (11) 765 (10) 178 (15) < 0.0001
Coronary artery bypass graft 384 (4) 303 (4) 81 (7) < 0.0001
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to admission was longer (p < 0.0001) than that of patients
without PolyVD (Table 2).
In-hospital mortality
The overall in-hospital mortality was 6.5% (n = 577), 7.2%
(n = 506) in patients with STEMI, 4.3% (n = 96) in NSTEMI
and 12.5% (n = 57) in patients with an undetermined elec-
trocardiographic pattern). A two-fold increase in hospital
mortality was observed in patients with PolyVD (p < 0.001)
compared to patients without PolyVD (Fig. 2A). Mortality was
highest in AMI patients with prior CVD or both prior CVD and
PAD (14% [n = 365]) and 13% (n = 77), respectively, vs. 9.8%
(n = 703) in patients with AMI and PAD and 5.7% (n = 7739) in
patients without PolyVD, (p < 0.001) (Fig. 2B).Values are number (%) or mean± standard deviation.
etween patients with and without PolyVD were assessed
y use of the t test or the 2-test as appropriate. Final
egression models were adjusted for age divided into three
ategories (< 60; 60—75; > 75 years) or as a continuous vari-
ble. A p value < 0.05 was considered signiﬁcant.
esults
aseline characteristics
mong the 9783 patients with AMI enrolled in the ﬁve reg-
stries between 2000 and 2005, 91% (n = 8904) had complete
atasets and constituted our study population. Clinical char-
cteristics are summarized in Table 1. Brieﬂy, the mean age
as 66± 14 years, 72% were men and the prevalence of
ardiovascular risk factors was high.
Among the 8904 patients, 4% (n = 356) patients had a
istory of stroke or TIA (CVD), 8% (n = 712) had a history
f PAD and 1% (n = 89) had a history of both CVD and
AD. Therefore, 13% (n = 1161) of patients had a history of
olyVD (Fig. 1). Patients with a history of PolyVD were older
p < 0.0001), had consistently more cardiovascular risk fac-
ors (all p < 0.005), but were less frequently obese (body
ass index ≥ 30 kg/m2) (p < 0.0001) (Table 1). They were
lso more likely to have a history of CAD (p < 0.0001) or renal
nsufﬁciency (p < 0.0001).
linical presentation
mong the 8904 patients analyzed, 70% (n = 6224) presented
ith STEMI, 25% (n = 2244) with NSTEMI, and 5% (n = 436) with
n undetermined electrocardiographic pattern.
Patients with prior PolyVD were less likely to present
ith STEMI (p < 0.0001) and more likely to have NSTEMI
p < 0.0001) or an undetermined electrocardiographic pat-
ern (p < 0.0001) than patients without PolyVD. They also
resented with a higher Killip class and a lower ejection
raction (both p < 0.0001) and the delay from symptom onset
Figure 1. Symptomatic polyvascular disease in acute myocardial
infarction: The Alliance consortium (n = 9783). CAD: coronary artery
disease; CVD: cerebrovascular disease; PAD: peripheral arterial dis-
ease.
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Figure 2. In-hospital mortality in patients with acute myocardial
infarction according to the (A) presence or absence of polyvascu-
Figure 3. In-hospital revascularization in patients with acute
myocardial infarction according to the presence of peripheral arte-
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Clar disease (PolyVD); (B) disease location (coronary artery disease
[CAD], cerebrovascular disease [CVD], peripheral arterial disease
[PAD]); and (C) age group.
Mortality increased sharply with age, from 1.7% in
patients aged < 60 years to 4.6% between 60 and 75 years,
and 11.8% after 75 years. Even though patients with
PolyVD were on average older than patients with CAD
alone, mortality remained higher across all age categories
(Fig. 2C) and remained higher after adjustment for age (odds
ratio [OR] 1.52, 95% conﬁdence interval [CI] 1.23—1.88,
p < 0.001) (Table 3). Similar results were observed after addi-
tional adjustment for the ﬁve registries (OR 1.50, 95% CI
1.23—1.82, p < 0.001).
In-hospital management
Procedures
During the index hospitalization, 84% (n = 7398) of patients
underwent coronary angiography, 59% (n = 5244) percuta-
neous coronary intervention (PCI), 23% (n = 2048) primary
PCI and 72% (n = 836) coronary artery bypass graft (CABG)
surgery. Compared to patients without PolyVD, patients with
prior PolyVD less frequently underwent coronary angiogra-
phy (72% [n = 839] vs 85% [n = 6582], p < 0.0001) or PCI (48%
[n = 560] vs 62% [n = 4470], p < 0.0001), whereas the rate of
CABG was similar (7% [n = 85] vs 7% [n = 542], p = 0.75), espe-
w
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mial disease (PAD), cerebrovascular disease (CVD), both, or coronary
rtery disease (CAD) alone. CABG: coronary artery bypass graft; PCI:
ercutaneous coronary intervention.
ially in patients with PAD (9%) (Table 2). Rates of primary
CI did differ between groups (p≤ 0.0001) (Fig. 3).
edical therapy
mong the 8327 patients discharged alive, 65% (n = 5373)
eceived statins, 71% (n = 5891) beta-blockers, 56% (n = 4696)
n angiotensin-converting enzyme (ACE) inhibitor or
ngiotensin receptor blocker (ARB) and 84% (n = 7012)
ntiplatelet therapy. Compared to patients with CAD alone,
atients with PolyVD were less frequently prescribed statins
60% vs 65%, p = 0.003) and beta-blockers (64% vs 72%,
< 0.0001), but more frequently received ACE inhibitors or
RBs (61% vs 56%, p < 0.002). The rate of antiplatelet therapy
as similar in both groups (85% vs 82%, p = 0.09).
iscussion
mong patients admitted to hospitals in France for AMI,
he presence of prior CVD or PAD was common, was asso-
iated with more cardiovascular risk factors and a more
evere clinical presentation. Patients with PolyVD less often
eceived guideline-recommended medications, underwent
ewer coronary percutaneous revascularization procedures
nd had a higher in-hospital morbidity compared to patients
ith CAD alone.
common and high-risk subgroup
n the present study, 13% of patients admitted for AMI had
ymptomatic PolyVD (rising to almost 20% in patients aged 75
ears and older), conﬁrming the strong association between
AD, CVD and CAD. The effect of PAD on hospital outcome
n patients admitted for ACS was evaluated in the GRACE
egistry [21]. Our study corroborates and extends previous
bservations to all patients with PolyVD, including PAD and
VD, using the resources of the Alliance project. Patients
ith prior PolyVD admitted for AMI had worse baseline
haracteristics (they were older, more likely to have renal
nsufﬁciency and a higher prevalence of cardiovascular risk
actors) and had higher in-hospital mortality. This increased
ortality rate was observed in all age categories and PolyVD
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Table 2 Clinical presentation and management of the overall population and according to the presence or absence of
polyvascular disease (PolyVD).
Variable Overall
(n = 8904)
No PolyVD
(n = 7743)
PolyVD
(n = 1161)
p
Type of acute coronary syndrome
ST-elevation myocardial infarction 6224 (70) 5523 (71) 701 (60) < 0.0001
Non-ST-elevation myocardial infarction 2244 (25) 1871 (24) 373 (32) < 0.0001
Undetermined 436 (5) 349 (4) 87 (8) < 0.0001
Killip class ≥2 2419 (27) 1959 (25) 460 (40) < 0.0001
GUSTO score mean (standard deviation) 23 (55) 24 (44) 23 (42) < 0.0001
Ejection fraction < 40% 739 (14) 609 (14) 130 (20) < 0.0001
Delay from symptom to admission (h)
< 3 2761 (35) 2450 (35) 311 (31) 0.012
< 6 4732 (60) 4197 (61) 535 (54) < 0.0001
< 12 6001 (76) 5274 (88) 727 (73) 0.039
Procedures
Coronary angiography 7398 (84) 6582 (85) 836 (72) < 0.0001
Percutaneous coronary intervention 5244 (59) 4470 (62) 560 (48) < 0.0001
Primary percutaneous coronary intervention 2048 (23) 1858 (24) 219 (19) < 0.0001
Coronary artery bypass graft 623 (7) 542 (7) 85 (7) 0.75
Medical therapy
Antiplatelet 7012 (84) 6166 (85) 846 (82) 0.09
Beta-blocker 5891 (71) 5232 (72) 659 (64) < 0.0001
Statin 5373 (65) 4753 (65) 620 (60) 0.003
ACE or ARB 4696 (56) 4071 (56) 625 (61) 0.002
Values are number (%). ACE: angiotensin-converting enzyme inhibitor;
Table 3 Age-adjusted case-fatality rates (referent:
coronary vascular disease alone).
Prior disease Odds ratio (95%
conﬁdence interval)
p
PAD 1.36 (1.03—1.79) 0.027
Stroke/TIA 1.74 (1.27—2.40) 0.001
Both PAD and
stroke/TIA
1.73 (0.87—3.44) 0.115
PolyVD 1.52 (1.23—1.88) < 0.001
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more severe heart failure or because of a fear of poten-PAD: peripheral arterial disease; PolyVD: polyvascular disease;
TIA: transient ischaemic attack.
as a strong and independent predictor of in-hospital mor-
ality. Thus, our data show that in patients admitted for AMI,
he extent of the atherosclerotic burden is associated with
orse in-hospital mortality. An important clinical implica-
ion of the present study is that a history of symptomatic
AD or CVD, which can be simply assessed by physicians in a
ew minutes, is a strong prognostic factor.
ess-aggressive management
espite the high prevalence of PolyVD and its strong associ-
tion with cardiovascular morbidity and mortality, PolyVD
as received relatively little attention in the context of
MI. Cardiovascular risk factors are less-often controlled in
atients with PAD and guideline-recommended medications
t
m
i
pARB: angiotensin receptor blocker.
antiplatelet therapy, beta-blockers, statins and ACE/ARBs
5—8,10,22]) are less often used despite the obvious beneﬁts
f these guideline-recommended medications on outcomes
12,23].
The present study documents less-aggressive manage-
ent of patients with prior PolyVD admitted for AMI, with
elayed times to admission, a lower procedural rate (angiog-
aphy), and less frequent use of guideline-recommended
edications at discharge. The rates of primary PCI were
imilar regardless of the presence or absence of PolyVD, sug-
esting that the more conservative management of polyVD
atients was related mostly to patients with NSTEMI. It is not
lear why higher risk patients with PolyVD underwent fewer
oronary procedures. Some physicians may decide to with-
old coronary angiography in this older population, who have
ore frequent comorbidities including renal insufﬁciency.
The underuse of guideline-recommended medications is
missed opportunity in patients eligible for these drugs,
ince if they are not introduced during the index hos-
italization, they are rarely initiated afterwards. Only
1% of patients with PolyVD received the four guideline-
ecommended medications. However, in the present study,
e could not investigate whether the differences in medica-
ion use between patients with and without PolyVD were or
ere not appropriate. It is possible that beta-blockers were
rescribed less frequently because patients with PolyVD hadial adverse effects in patients with PAD or in patients with
ore frequent history of smoking. The lower use of statins
n patients with PolyVD is less easy to understand, as multi-
le studies have demonstrated the consistent effectiveness
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of statin therapy in patients presenting with AMI regardless
of their clinical proﬁle.
Thus, despite a higher risk proﬁle and a greater inci-
dence of comorbidities, patients with a history of PAD or
CVD were less likely to receive effective cardiac medications
and interventional procedures. Even if it would appear intu-
itive, whether these treatment disparities contributed to
the observed difference in hospital mortality is not entirely
clear and cannot be inferred from the present data. Nev-
ertheless, guideline-recommended medications should be
strongly recommended in this high-risk subgroup [24]. In
the GRACE registry, improvement in the clinical outcome
resulting from changes in pharmacological and procedu-
ral care of patients with AMI was independent of the risk
status of the study population [9], and use of guideline-
recommended medications was associated with improved
outcome in all subgroups [25]. In addition, use of a combi-
nation of guideline-recommend medications was associated
with lower 6-month mortality, with an incremental and syn-
ergistic effect [24]. These ﬁndings suggest a need for further
evaluation of treatment decisions in patients with PolyVD
presenting with an AMI and demonstrate considerable oppor-
tunity to improve the outcomes of these high-risk patients.
Future clinical trials will evaluate the impact of an aggres-
sive atherosclerosis risk-factor management and strategy on
outcomes in patients with PolyVD admitted for AMI.
Limitations
The Alliance project is an observational study gathering
data from ﬁve different registries and is therefore subject
to inherent limitations particularly related to the potential
heterogeneity between studies [26]. However, deﬁnitions
were homogeneous and endpoints (medications, coronary
intervention or total death) were unambiguous and easy to
ascertain. Almost all (91%) of the patients in these ﬁve stud-
ies contributed data to the pooled analysis, therefore it is
unlikely that patient selection created bias. Furthermore,
an excess mortality in patients with PolyVD was observed in
each registry (ORs ranging from 1.21 to 1.85) and the excess
mortality in PolyVD patients was also observed after adjust-
ment for the type of registry. Another concern relates to the
fact that the use of additional key therapies such as clopi-
dogrel or glycoprotein IIb/IIIa inhibitors was not recorded in
each registry and therefore could not be analysed, yet their
underuse may have contributed to the higher mortality of
PolyVD patients. Third, PolyVD was self-reported. This may
lead to under-diagnosis of PAD or CVD, and whether our ﬁnd-
ings can be extrapolated to patients with asymptomatic PAD
or CVD deserves further investigation. Finally, the present
study did not evaluate long-term morbidity and mortality.
Conclusion
Polyvascular disease is frequent among patients admitted
for AMI and is an easy and simple predictor of out-
come. Despite a more severe clinical presentation and
a worst outcome, patients with PolyVD received fewer
guideline-recommended medications and had fewer coro-
nary procedures performed, which may explain, at least
partially, their higher in-hospital mortality. These results213
emonstrate considerable opportunity to improve the out-
ome of these high-risk patients. Flagging patients with
nown PolyVD early after admission and early recognition of
heir intrinsic poor prognosis may help clinicians to ensure
hat they receive appropriate care while in hospital and are
rescribed evidence-based medications at discharge.
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